|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
81,510,000 |
Market
Cap: |
1.96(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$17.69 - $45.07 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Beam Therapeutics is a biotechnology company. Co. has identified four development candidates to date: three from its ex vivo platform, with two candidates targeting hemoglobinopathies and one candidate targeting T-cell leukemia, and one from its in vivo platform targeting glycogen storage disease. BEAM-102 directly corrects the causative mutation in sickle cell disease by recreating a naturally-occurring normal human hemoglobin variant, HbG-Makassar. BEAM-201 is an anti-CD7, multiplex edited, allogeneic chimeric antigen receptor T cell development candidate for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
1,076,735 |
1,092,090 |
1,249,399 |
1,667,862 |
Total Sell Value |
$32,842,473 |
$33,262,334 |
$38,301,409 |
$57,111,391 |
Total People Sold |
6 |
6 |
6 |
6 |
Total Sell Transactions |
10 |
13 |
17 |
42 |
End Date |
2024-01-21 |
2023-10-20 |
2023-04-21 |
2022-04-21 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Simon Amy |
Chief Medical Officer |
|
2024-04-02 |
4 |
AS |
$30.54 |
$504,851 |
D/D |
(16,530) |
70,060 |
|
-22% |
|
Simon Amy |
Chief Medical Officer |
|
2024-04-01 |
4 |
AS |
$32.13 |
$229,954 |
D/D |
(7,157) |
86,590 |
|
-27% |
|
Bellon Christine |
Chief Legal Officer |
|
2024-04-01 |
4 |
AS |
$32.12 |
$109,240 |
D/D |
(3,401) |
104,594 |
|
-27% |
|
Burrell Terry-Ann |
Chief Financial Officer |
|
2024-04-01 |
4 |
AS |
$32.12 |
$174,926 |
D/D |
(5,446) |
70,137 |
|
-27% |
|
Evans John M. |
CEO |
|
2024-04-01 |
4 |
AS |
$32.13 |
$581,617 |
D/D |
(18,102) |
1,058,343 |
|
-27% |
|
Ciaramella Giuseppe |
President |
|
2024-04-01 |
4 |
AS |
$32.12 |
$145,632 |
D/D |
(4,534) |
169,616 |
|
-27% |
|
Simon Amy |
Chief Medical Officer |
|
2024-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
27,500 |
93,747 |
|
- |
|
Bellon Christine |
Chief Legal Officer |
|
2024-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
27,500 |
107,995 |
|
- |
|
Ciaramella Giuseppe |
President |
|
2024-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
174,150 |
|
- |
|
Burrell Terry-Ann |
Chief Financial Officer |
|
2024-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
27,500 |
75,583 |
|
- |
|
Evans John M. |
CEO |
|
2024-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
77,500 |
1,076,445 |
|
- |
|
Evans John M. |
CEO |
|
2024-03-28 |
4 |
AS |
$33.86 |
$2,031,402 |
D/D |
(60,000) |
998,262 |
|
-28% |
|
Fmr Corp |
See Remark 1 |
|
2024-02-14 |
4 |
S |
$30.51 |
$27,496,912 |
I/I |
(900,000) |
1,235,511 |
|
24% |
|
Fmr Corp |
See Remark 1 |
|
2024-02-13 |
4 |
S |
$30.28 |
$48,139 |
I/I |
(1,565) |
2,771,913 |
|
20% |
|
Evans John M. |
CEO |
|
2024-01-31 |
4 |
AS |
$25.33 |
$1,519,800 |
D/D |
(60,000) |
1,058,262 |
|
-2% |
|
Bellon Christine |
Chief Legal Officer |
|
2024-01-03 |
4 |
AS |
$26.42 |
$50,383 |
D/D |
(1,907) |
80,495 |
|
-7% |
|
Fmr Corp |
See Remark 1 |
|
2023-12-22 |
4 |
D |
$0.00 |
$0 |
I/I |
(29,549) |
2,773,478 |
|
- |
|
Bellon Christine |
Chief Legal Officer |
|
2023-11-20 |
4 |
AS |
$30.00 |
$305,000 |
D/D |
(10,000) |
82,402 |
|
-1% |
|
Bellon Christine |
Chief Legal Officer |
|
2023-11-20 |
4 |
OE |
$7.22 |
$72,200 |
D/D |
10,000 |
92,402 |
|
- |
|
Simon Amy |
Chief Medical Officer |
|
2023-10-30 |
4 |
AS |
$18.70 |
$64,478 |
D/D |
(3,448) |
65,469 |
|
91% |
|
Ciaramella Giuseppe |
President and CSO |
|
2023-10-20 |
4 |
OE |
$0.67 |
$60,903 |
D/D |
90,900 |
139,150 |
|
- |
|
Bellon Christine |
Chief Legal Officer |
|
2023-10-02 |
4 |
AS |
$22.85 |
$8,866 |
D/D |
(388) |
82,402 |
|
35% |
|
Ciaramella Giuseppe |
President and CSO |
|
2023-07-24 |
4 |
AS |
$32.01 |
$38,604 |
D/D |
(1,206) |
48,250 |
|
-9% |
|
Ciaramella Giuseppe |
President and CSO |
|
2023-07-24 |
4 |
OE |
$7.22 |
$8,707 |
D/D |
1,206 |
49,456 |
|
- |
|
Ciaramella Giuseppe |
President and CSO |
|
2023-07-21 |
4 |
AS |
$32.06 |
$4,979,687 |
D/D |
(155,324) |
48,250 |
|
-7% |
|
168 Records found
|
|
Page 1 of 7 |
|
|